Press Release: MMIT Announces Winners of the Q1 2022 Patient Access Awards
Winners across eight therapeutic areas are recognized by payers and physicians for their dedication to smoothing patient access
June 23, 2022, Yardley, PA – Managed Markets Insight & Technology (MMIT)—the trusted go-to-market partner for overcoming barriers to patient access—has launched the inaugural Patient Access Awards to honor pharmaceutical manufacturers committed to improving patient access to life-saving therapies.
“We’re thrilled to recognize the critical role that manufacturers play in the success of a patient’s healthcare journey,” said Diane Watson, CEO of MMIT, a Norstella company. “Our hope is that this recognition inspires the industry to continue working to ensure that much-needed therapies get into the hands of the patients who need them.”
The winners—one per therapeutic area—are determined by payer and physician stakeholders, who are surveyed as part of MMIT’s quarterly Oncology Index and Biologics and Injectables Index.
In this research, payer and physician stakeholders assess and rank the performance of pharmaceutical manufacturers across a series of factors, including their overall commitment to a disease, account representative support, patient and family support programs and resources, patient copay assistance, physician education, and support and HUB services.
“MMIT extends a heartfelt congratulations to each of the winners,” said Watson. “We’re so proud to recognize your success and admirable dedication to patients.”
The winners of the inaugural Patient Access Awards are:
- Novartis (Breast Cancer)
- Merck & Co. (Metastatic Melanoma)
- Bristol-Myers Squibb (Non-Small Cell Lung Cancer)
- Bristol-Myers Squibb (Bladder Cancer)
Biologics & Injectables:
- CSL Behring (Hereditary Angioedema)
- Pfizer, Inc. (Growth Hormone Deficiency)
- Janssen Pharmaceuticals (Rheumatoid Arthritis)
- Novartis (Multiple Sclerosis)
Learn more information about the Patient Access Awards.
MMIT, a Norstella company, is focused on solving the “what and why” of market access, and has been a trusted, go-to-market partner to more than 1,300 biopharma and payer customers for nearly three decades. MMIT believes that patients who need life-saving treatments should not face delays because accessing drugs can be confusing. MMIT’s expert teams of clinicians, data specialists and market researchers provide clarity and confidence so that our clients can make better decisions. For more information, visit mmitnetwork.com and follow us on LinkedIn.